Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06553976 · ClinicalTrials.gov registry record

Spastic Paraplegia - Centers of Excellence Research Network

A clinical trial of Neuromuscular Diseases and Primary Lateral Sclerosis, sponsored by Boston Children's Hospital.

Recruiting
Registry status
100
Enrollment target
11
Study locations

NCT06553976: Recruiting study of Neuromuscular Diseases and Primary Lateral Sclerosis, sponsored by Boston Children's Hospital.

NCT06553976 is a study of Neuromuscular Diseases and Primary Lateral Sclerosis that is actively recruiting participants, run by Boston Children's Hospital. The registered enrollment target is 100 participants, below the 125-participant average among 15 other Neuromuscular Diseases trials with a reported enrollment target (20% lower). The trial reports 11 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06553976, a study of Neuromuscular Diseases and Primary Lateral Sclerosis, is actively recruiting participants, sponsored by Boston Children's Hospital.

RECRUITING
Registry status
100 participants
Enrollment target
11
Study locations

Study Summary

The Spastic Paraplegia - Centers of Excellence Research Network (SP-CERN) is a collaborative research consortium dedicated to advancing the understanding, diagnosis, and treatment of hereditary spastic paraplegia (HSP) and primary lateral sclerosis (PLS). Aims of the consortium are to a) perform natural history studies of HSP subtypes, b) discover and validate biomarkers and clinician- and patient-reported outcome measures, c) uncover HSP's molecular pathophysiology and develop rational therapeutic targets, and d) perform sufficiently powered clinical trials. The current pilot study is aimed at enrolling 100 individuals with hereditary spastic paraplegia type 4 (SPG4) or hereditary spastic paraplegia type 5A (SPG5A).

Conditions Studied

Neuromuscular Diseases Primary Lateral Sclerosis Hereditary Spastic Paraplegia Early Onset Hereditary Spastic Paraplegia SPG4 SPG5A Spastic Paraplegia 4 Spastic Paraplegia 5A Spastic Paraplegia, Hereditary

Study Locations (11)

Massachusetts

  • Boston Children's Hospital - Boston
  • Massachusetts General Hospital - Boston

Texas

  • Scottish Rite for Children - Dallas
  • Texas Children's Hospital - Houston

Washington

  • Seattle Children's Hospital - Seattle
  • University of Washington School of Medicine - Seattle

Florida

  • University of Miami Miller School of Medicine - Miami

Iowa

  • University of Iowa Carver College of Medicine - Iowa City

Michigan

  • University of Michigan School of Medicine - Ann Arbor

New York

  • Columbia University - Irving Medical Center - New York

Ohio

  • Cincinnati Children's Hospital Medical Center - Cincinnati

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2024-06-04
Est. Completion 2027-06-04
Boston Children's Hospital

462 total trials

What NCT06553976 shows while recruiting

NCT06553976 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 125-participant average among 15 other Neuromuscular Diseases trials with a reported enrollment target (20% lower).

The record links to 9 conditions, with Neuromuscular Diseases appearing as the primary indexed condition, and to 0 interventions.

NCT06553976 lists 11 locations in 8 states (Massachusetts, Texas, Washington).

Frequently Asked Questions

What is clinical trial NCT06553976 about?

NCT06553976 is a clinical study titled "Spastic Paraplegia - Centers of Excellence Research Network". The Spastic Paraplegia - Centers of Excellence Research Network (SP-CERN) is a collaborative research consortium dedicated to advancing the understanding, diagnosis, and treatment of hereditary spastic paraplegia (HSP) and primary lateral sclerosis (PLS). Aims of the consortium are to a) perform nat...

What is the current status of trial NCT06553976?

This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2024-06-04. Estimated completion is 2027-06-04.

What conditions does trial NCT06553976 study?

This clinical trial studies the following conditions: Neuromuscular Diseases, Primary Lateral Sclerosis, Hereditary Spastic Paraplegia, Early Onset Hereditary Spastic Paraplegia, SPG4.

Who is sponsoring clinical trial NCT06553976?

This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06553976 being conducted?

This trial has 11 study locations across Florida, Iowa, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neuromuscular Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06553976's enrollment target sits among peer trials

100 7th of 15 higher than 9 of 15 other Neuromuscular Diseases trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Neuromuscular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06553976

Source: ClinicalTrials.gov NCT06553976, the US trial registry maintained by the National Library of Medicine. NCT06553976 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.